AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
Dutch biotech Pharming plans to challenge big pharma in rare diseasesThe introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this Share XDutch biotech Pharming plans to challenge big pharma in rare diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/pharming-challenge-pharma-rare-diseases/
Four steps for more patient centric trialsMedidata’s general manager & senior vice president EMEA, Christian Hebenstreit, on placing the patient experience at the heart Share XFour steps for more patient centric trialshttps://pharmaphorum.com/r-d/views-analysis-r-d/four-steps-patient-centric-trials/
Is the pharma gender gap starting to close?When Emma Walmsley took the reins of GlaxoSmithKline (GSK) in 2016, becoming the first woman to head up Share XIs the pharma gender gap starting to close?https://pharmaphorum.com/views-analysis-sales-marketing/is-the-pharma-gender-gap-starting-to-close/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
Commercialising orphan drugs: the pharmaphorum podcastIn episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Share XCommercialising orphan drugs: the pharmaphorum podcasthttps://pharmaphorum.com/r-d/views-analysis-r-d/orphan-drugs-pharmaphorum-podcast/
Merck KGaA’s bold new approach to cancer immunotherapyGermany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer Share XMerck KGaA’s bold new approach to cancer immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/
Calliditas pushing on with kidney disease drug after IPO successCalliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it Share XCalliditas pushing on with kidney disease drug after IPO successhttps://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/
Boosting clinical trial productivity to prove Eroom wrongAccording to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least Share XBoosting clinical trial productivity to prove Eroom wronghttps://pharmaphorum.com/r-d/boosting-clinical-trial-productivity-to-prove-eroom-wrong/
